Navigation Links
Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
Date:12/15/2008

BRIDGEWATER, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S., an affiliate of sanofi-aventis, one of the world's leading pharmaceutical companies, announced today that starting January 1, 2009, it has increased access to its non-oncology Patient Assistance Programs (PAP)s to include eligible uninsured patients with incomes up to 250% of the Federal Poverty Level.

These PAPs assist patients with limited financial resources in gaining access to needed sanofi-aventis U.S. prescription medicines by focusing on individual patients and acting as a resource for those patients and their advocates. Uninsured individuals with income levels of up to $26,000 and uninsured families of four with combined income of up to $53,000 may be eligible to receive sanofi-aventis U.S. prescription drugs at no charge through the expanded U.S. Traditional PAP.*

"Sanofi-aventis U.S. remains committed to making our prescription medicines available to uninsured and low income patients through our PAPs," stated Greg Irace, President and CEO of sanofi-aventis U.S. "We have taken several steps to help patients with the greatest financial need access these medications."

The sanofi-aventis U.S. Patient Assistance Programs include medicines for many different disease states, including: Diabetes, Rheumatoid Arthritis, Urology, Dermatology, Blood Clotting (Deep Vein Thrombosis, Pulmonary Embolism), and Allergies. For more information, please contact the sanofi-aventis U.S. Traditional PAP at 1-800-221-4025.

PACT+(R) (Providing Access to Cancer Therapy), is Sanofi-aventis U.S.'s PAP for Cancer medications. PACT+ provides access to our oncology brands for eligible low income patients with an income of no greater than 500 percent of the Federal Poverty Level. PACT+ also provides reimbursement support services plus offers help in identifying a variety of alternative services and resources to support the specific needs of cancer patients. For more information on PACT+, please call 1-800-996-6626.

In addition, sanofi-aventis U.S. is a proud participant in The Partnership for Prescription Assistance which brings together America's pharmaceutical companies, doctors, other health care providers, patient advocacy organizations and community groups to help qualifying patients who lack prescription coverage get the medicines they need through the public or private program that's right for them. Call 1-888-477-2669 or visit www.pparx.org.

*Federal Poverty Limits change annually and are issued by the US Department of Health and Human Services.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, visit: www.sanofi-aventis.us or www.sanofi-aventis.com

Contact: Marc Greene, sanofi-aventis, 212-551-4780


'/>"/>
SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
2. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
3. Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1):
4. Sanofi-aventis Teams With HHS Quality Agency to Distribute Consumer Health Materials
5. Sanofi-aventis Named One of Best Employers for Healthy Lifestyles by National Business Group on Health
6. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
7. TechTeam Global Will Provide Multilingual EDC Support Services for sanofi-aventis recherche & developpement
8. Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
9. Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
10. Sanofi-aventis US Chairman Tim Rothwell Addresses CMSAs Collaborative Practice Summit
11. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... “I Forgive You”: a fine examination of how God handles sin, including how to ... author, Stephen Miller, who, for over ten long years has been waiting to release this ... and Tobago, he has been serving the Lord for over twenty years, and he has ...
(Date:1/20/2017)... ... ... “The Land of More and More”: a brilliant story for children ... the simple and achievable answer. “The Land of More and More” is the creation ... in Angola, Indiana where he works with the children’s ministry department. , Michael ...
(Date:1/19/2017)... ... 2017 , ... Wells Pharmacy Network announced the completion of ... pharmacy located in Ocala, Florida. , Meeting the Needs of a Growing ... States for high-quality human anti-aging and wellness compounded medications, Wells Pharmacy ...
(Date:1/19/2017)... ... January 19, 2017 , ... Remote Medical Technologies ... impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound System. Compatible ... technology that delivers HD, dynamic, streaming ultrasound images and video to one or ...
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business Capital, ... $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro ... facilitate a recapitalization of MedPro led by Harren Equity Partners. Brightwood Capital ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Fla. , Jan. 19, 2017  Sensus ... medical device company specializing in the treatment of ... as keloids, with superficial radiation therapy, today announced ... full year 2016 financial results on Thursday, February 2, ... Company will hold a conference call with the ...
(Date:1/19/2017)... , January 19, 2017 ... announced that the U.S. Food and Drug Administration (FDA) ... a New Drug Application (NDA) for SHP465, a long-acting, ... as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). ... or around June 20, 2017, the designated Prescription Drug ...
(Date:1/19/2017)... January 19, 2017 Pfizer ... the Milner Therapeutics Consortium   Major ... Cambridge   The Milner ... PFE ) as a partner to the Milner Therapeutics ... enables the efficient transfer of materials between industry and ...
Breaking Medicine Technology: